Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 0.0% | 360.7% | 75.2% | 41.0% | 33.2% | 24.9% | 20.6% | (903.8%) | 398.3% | (860.4%) | (27.3%) | (48.9%) | (28.9%) | (177.6%) | (41.1%) | (49.9%) |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is (83.6%), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for Aadi Bioscience, Inc. have been (62.1%) over the past three years, and (60.4%) over the past five years.
As of today, Aadi Bioscience, Inc.'s Return on Equity (ROE) is (83.6%), which is lower than industry median of (52.7%). It indicates that Aadi Bioscience, Inc.'s Return on Equity (ROE) is Bad.